Search Results

You are looking at 71 - 80 of 550 items for :

  • Refine by Access: All x
Clear All
Full access

A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque, and David G. Pfister

The median number of treatment cycles delivered was 2 for both groups (ranges, <1–13 for Group A; <1–15 for Group B). The most common cetuximab-related adverse events (all grades) among treated subjects included rash, fatigue, and hypomagnesemia

Full access

Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma

Luxi Chen, John Davelaar, Srinivas Gaddam, Kambiz Kosari, Nicholas Nissen, George Chaux, Christopher Lee, Eric Vail, Andrew Hendifar, Jun Gong, Karen Reckamp, and Arsen Osipov

abdominal pain. He experienced a significant unintentional 35-pound weight loss over 6 months with associated fatigue, loss of appetite, abdominal pain, and light-colored stools. Physical examination findings were notable for scleral icterus and jaundice. In

Full access

Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia

Sandipkumar H. Patel, Sumithira Vasu, Ling Guo, Olivia Lemaster, John C. Byrd, and Alison Walker

had been well until 1 month before admission, when she noted fatigue, a 25-pound weight loss with concurrent otitis media, and sinus infections lasting 4 weeks. She was evaluated by her primary care physician and found to have new-onset anemia and

Full access

Outcomes From a Patient-Centered, Interprofessional, Palliative Consult Team in Oncology

Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah

study can be found on the Alberta Health Services website. 11 Edmonton Symptom Assessment System: The ESAS 12 is a self-report questionnaire that asks patients to rate the severity of their current suffering regarding 9 common symptoms (pain, fatigue

Full access

Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?

Kamya Sankar and Brady L. Stein

provided molecular targets for drug development in both PV and ET. The primary goals of treatment for MPNs are to reduce the risk of thrombosis and alleviate systemic symptom burden (eg, fatigue, pruritus, microvascular symptoms, symptomatic splenomegaly

Full access

Personalizing Medicine Through Personalized Communication: Individuality of the Patient Across Borders and Cultures

Giuseppe Curigliano

in all geo-cultural groups are particularly traumatized by the overt physical changes from breast cancer treatments. The stigmata of breast surgery and of treatment-related side effects such as hair loss and fatigue confirm to women the reality of

Full access

Are We on the Same Page? Patient and Provider Perceptions About Exercise in Cancer Care: A Focus Group Study

Agnes Smaradottir, Angela L. Smith, Andrew J. Borgert, and Kurt R. Oettel

mentioned fatigue most often as a significant barrier to exercise (50%). Other barriers included symptoms of disease, such as dyspnea, pain, and impaired mobility. Side effects of treatment, including nausea, vomiting, diarrhea, neuropathic pain, emotional

Full access

Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

survival. 1 Proposed mechanisms for this positive effect on chemotherapy treatment tolerance include exercise-related amelioration of specific symptoms or toxicities that cause treatment reductions or delays, including neutropenia, fatigue, and neuropathy

Full access

Discussing Colorectal Cancer

Paul F. Engstrom

Full access

Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia

Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre, and James Rosberg

. Factors influencing quality of life in cancer patents: anemia and fatigue . Semin Oncol 1998 ; 25 : 43 – 46 . 4 Curt GA . Impact of fatigue on quality of life in oncology patients . Semin Hematol 2000 ; 37 : 14 – 17 . 5 Sobrero